PAK4 and prostate carcinoma: Recent studies have demonstrated that the inhibition of PAK4 increased CD8+ T cell infiltration in immune-resistant melanoma and prostate cancer and synergized with immune checkpoint inhibitors in suppressing cancer growth [12,13,14].